These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

373 related items for PubMed ID: 17390741

  • 1. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
    Budde K, Bosmans JL, Sennesael J, Zeier M, Pisarski P, Schütz M, Fischer W, Neumayer HH, Glander P.
    Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
    [Abstract] [Full Text] [Related]

  • 2. Enteric-coated mycophenolate sodium in combination with full dose or reduced dose cyclosporine, basiliximab and corticosteroids in Australian de novo kidney transplant patients.
    Chadban S, Eris J, Russ G, Campbell S, Chapman J, Pussell B, Trevillian P, Ierino F, Thomson N, Hutchison B, Irish A, Woodcock C, Kurstjens N, Walker R, MyProms AU01 Study Group.
    Nephrology (Carlton); 2013 Jan; 18(1):63-70. PubMed ID: 23110508
    [Abstract] [Full Text] [Related]

  • 3. Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients.
    Cibrik D, Meier-Kriesche HU, Bresnahan B, Wu YM, Klintmalm G, Kew CE, Kuo PC, Whelchel J, Cohen D, Baliga P, Akalin E, Benedetti E, Wright F, Lieberman B, Ulbricht B, Jensik S, Myfortic-US01 Renal Transplant Study Group.
    Clin Transplant; 2007 Jan; 21(2):192-201. PubMed ID: 17425744
    [Abstract] [Full Text] [Related]

  • 4. Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.
    Oh CK, Huh KH, Ha J, Kim YH, Kim YL, Kim YS.
    Transplantation; 2015 Jan; 99(1):180-6. PubMed ID: 24983307
    [Abstract] [Full Text] [Related]

  • 5. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
    Kato Y, Tojimbara T, Iwadoh K, Koyama I, Nanmoku K, Kai K, Sannomiya A, Nakajima I, Fuchinoue S, Teraoka S.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1984-92. PubMed ID: 17161352
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids.
    Offner G, Toenshoff B, Höcker B, Krauss M, Bulla M, Cochat P, Fehrenbach H, Fischer W, Foulard M, Hoppe B, Hoyer PF, Jungraithmayr TC, Klaus G, Latta K, Leichter H, Mihatsch MJ, Misselwitz J, Montoya C, Müller-Wiefel DE, Neuhaus TJ, Pape L, Querfeld U, Plank C, Schwarke D, Wygoda S, Zimmerhackl LB.
    Transplantation; 2008 Nov 15; 86(9):1241-8. PubMed ID: 19005406
    [Abstract] [Full Text] [Related]

  • 7. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil.
    Vincenti F, Monaco A, Grinyo J, Kinkhabwala M, Roza A.
    Am J Transplant; 2003 Mar 15; 3(3):306-11. PubMed ID: 12614286
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of everolimus with reduced-exposure cyclosporine in de novo kidney transplant patients at increased risk for efficacy events: analysis of a randomized trial.
    Carmellini M, Garcia V, Wang Z, Vergara M, Russ G.
    J Nephrol; 2015 Oct 15; 28(5):633-9. PubMed ID: 25708913
    [Abstract] [Full Text] [Related]

  • 9. Report of the experience with enteric-coated sodium mycophenolate in a de novo population of kidney transplant recipients at high risk for delayed graft function.
    Novoa P, Rodríguez L, Gutiérrez L.
    Transplant Proc; 2007 Apr 15; 39(3):600-1. PubMed ID: 17445554
    [Abstract] [Full Text] [Related]

  • 10. A single-centre, open-label, prospective study of an initially short-term intensified dosing regimen of enteric-coated mycophenolate sodium with reduced cyclosporine A exposure in Chinese live-donor kidney transplant recipients.
    Cai L, Zeng F, Liu B, Wei L, Chen Z, Jiang J.
    Int J Clin Pract Suppl; 2014 Apr 15; (181):23-30. PubMed ID: 24673716
    [Abstract] [Full Text] [Related]

  • 11. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS, Irfan Saeed M, Ranganna K, Malat G, Sustento-Reodica N, Kumar AM, Meyers WC.
    Transpl Immunol; 2008 Nov 15; 20(1-2):32-42. PubMed ID: 18773960
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies.
    Legendre C, Cohen D, Zeier M, Rostaing L, Budde K.
    Transplant Proc; 2007 Jun 15; 39(5):1386-91. PubMed ID: 17580145
    [Abstract] [Full Text] [Related]

  • 13. Enteric-coated mycophenolate sodium in de novo pediatric renal transplant patients.
    Niaudet P, Charbit M, Loirat C, Lapeyraque AL, Tsimaratos M, Cailliez M, Foulard M, Dehennault M, Marquet P, Chaouche-Teyara K, Lemay D.
    Pediatr Nephrol; 2009 Feb 15; 24(2):395-402. PubMed ID: 18985393
    [Abstract] [Full Text] [Related]

  • 14. Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients.
    Glander P, Sommerer C, Arns W, Ariatabar T, Kramer S, Vogel EM, Shipkova M, Fischer W, Zeier M, Budde K.
    Clin J Am Soc Nephrol; 2010 Mar 15; 5(3):503-11. PubMed ID: 20150450
    [Abstract] [Full Text] [Related]

  • 15. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
    Mattei MF, Redonnet M, Gandjbakhch I, Bandini AM, Billes A, Epailly E, Guillemain R, Lelong B, Pol A, Treilhaud M, Vermes E, Dorent R, Lemay D, Blanc AS, Boissonnat P.
    J Heart Lung Transplant; 2007 Jul 15; 26(7):693-9. PubMed ID: 17613399
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function.
    Andrés A, Marcén R, Valdés F, Plumed JS, Solà R, Errasti P, Lauzurica R, Pallardó L, Bustamante J, Amenábar JJ, Plaza JJ, Gómez E, Grinyó JM, Rengel M, Puig JM, Sanz A, Asensio C, Andrés I, NI2A Study Group.
    Clin Transplant; 2009 Jul 15; 23(1):23-32. PubMed ID: 18798851
    [Abstract] [Full Text] [Related]

  • 17. Use of enteric-coated mycophenolate sodium in de novo renal transplant recipients with high incidence of delayed graft function.
    Schiavelli R, Gaite L, Agost Carreno C, Baran M, Novoa P, Massari P, Otero AB, Piulats E.
    Transplant Proc; 2006 Apr 15; 38(3):905-8. PubMed ID: 16647505
    [Abstract] [Full Text] [Related]

  • 18. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O, Wiesener M, Opgenoorth M, Pascher A, Woitas RP, Witzke O, Jaenigen B, Rentsch M, Wolters H, Rath T, Cingöz T, Benck U, Banas B, Hugo C.
    Lancet; 2016 Dec 17; 388(10063):3006-3016. PubMed ID: 27871759
    [Abstract] [Full Text] [Related]

  • 19. Basiliximab lowers the cyclosporine therapeutic threshold in the early post-kidney transplant period.
    Balbontin F, Kiberd B, Fraser A, Kiberd M, Lawen J.
    Clin Transplant; 2005 Apr 17; 19(2):225-9. PubMed ID: 15740559
    [Abstract] [Full Text] [Related]

  • 20. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion.
    Thervet E, Pfeffer P, Scolari MP, Toselli L, Pallardó LM, Chadban S, Pilmore H, Connolly J, Buchler M, Schena FP, Carreño CA, Dandavino R, Cole E.
    Transplantation; 2003 Sep 27; 76(6):903-8. PubMed ID: 14508352
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.